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Abstract 
 Candida albicans is a normal inhabitant of the skin and mucosal membranes of 
humans, however, in individuals with depressed immune systems or disrupted cutaneous 
flora, Candida can overgrow and cause serious infection. Candida infection is the fourth 
leading cause of nosocomial infection in the United States. These infections are often 
associated with longer hospital stays and higher mortality. Current drug therapies for this 
infection are largely ineffective due to the increased drug resistance of Candida species, 
and for some therapeutics, high levels of drug toxicity to humans. Histatin 5 is a naturally 
occurring salivary peptide that has strong antifungal properties. Derivatives of this 
peptide, including KM12 and KM23, have been previously tested in the McNabb lab, and 
have shown as much as ten times more fungicidal activity than Histatin 5. Our current 
understanding of the mechanism by which these peptides kill has not been fully 
characterized.  This study uses Saccharomyces cerevisiae as a genetically tractable model 
to investigate one of the proposed target mechanisms of KM23, namely respiratory 
metabolism. Respiratory mutants were tested to determine which gene knockouts 
conferred cell resistance to KM23. If resistance was present for the mutant, the 
corresponding gene product is part of the killing mechanism of KM23. ATP synthase 
mutants, atp1Δ, atp2Δ, atp5Δ, and atp7Δ, were the main focus of this study. It was found 
that atp1Δ, atp5Δ, and atp7Δ conferred resistance of the yeast cells to KM23, while atp2Δ 
did not show significant resistance. It was subsequently found that atp2Δ was not truly 
respiratory deficient, therefore, we conclude that ATP synthase function is imperative to 
the overall killing action of KM23, supporting prior observations that respiratory 
metabolism is necessary for killing by Histatin 5 and Histatin 5-related peptides. 
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Introduction 
Candida albicans is a species of fungi that inhabits the human body on the skin and in 
mucosal membranes. This organism is an opportunistic pathogen, meaning that it lives on 
the human body harmlessly as part of the normal flora, until the host’s immune response 
is lowered, due to other concurrent diseases or certain drug therapies. Candida albicans is 
a unicellular, diploid fungus that exists in 3 phases: budding yeast, pseudohyphae, and 
hyphae (Calderone & Fonzi, 2001). At room temperature and under anaerobic conditions, 
Candida albicans exists in the budding yeast form. In this state, the yeast colonies are 
oval-shaped, smooth, and white or cream colored (Calderone & Fonzi, 2001). However, 
under physiological conditions, this organism can convert to the hyphal or pseudohyphal 
form. In these filamentous states, the cells remain attached to each other after budding 
and elongate to form filaments, which are tubular, thread-like structures (Sudbery, Gow, 
Berman, 2004). This dimorphism is thought to aid in the virulence of Candida albicans 
(Calderone & Fonzi, 2001).  
 
Candida infections manifest in three main types: oropharyngeal candidiasis, genital or 
vulvovaginal candidiasis, and systemic candidiasis. These infections occur due to an 
overgrowth of Candida species caused by a lowered host immune response or a reduction 
in other resident bacteria that normally compete with this organism. In intensive care 
units worldwide, candidemia infection has a prevalence of 6.9 per 1000 patients 
(Mikulska M, 2012). Individuals who are most affected by candidiasis include 
immunocompromised patients, such as those undergoing treatment for HIV/AIDS or 
cancer, low-birth-weight infants, diabetics, and individuals using corticosteroids or 
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broad-spectrum antibiotics (CDC 2014). Candidiasis is associated with high mortality 
and increased hospital stays (Paramythiotou E, 2014). It is estimated that the mortality 
attributable to candidiasis is 19-24% (Morgan J 2005). A yeast infection in the mouth or 
throat, commonly termed “thrush”, if left unchecked could enter the bloodstream and 
spread systemically, causing further complications in a patient’s condition. Candida 
infections are the fourth most common nosocomial bloodstream infection in the United 
States (Paramythiotou E, 2014).  
 
There are multiple classes of antifungal drugs currently on the market, which attack 
different aspects of Candida species to treat infections. These drug classes include azoles, 
polyenes, pyrimidine analogs, and echinocandins. Azoles, such as miconazole and 
fluconazole, are the most commonly prescribed (Paramythiotou E, 2014). This class 
affects the composition of fungal plasma membranes through the inhibition of ergosterol 
synthesis by binding to the cytochrome P-450-dependent enzyme lanosterol demethylase 
in the fungal cell (Sheehan, Hitchcock, Sibley, 1999). This is an effective drug 
mechanism because mammalian cell membranes contain cholesterol rather than 
ergosterol, and because azoles have a greater affinity for the fungal enzyme associated 
with sterol synthesis than they do for the mammalian enzyme. However, the incidences 
of azole-resistant strains of Candida species has risen in recent years due to chronic use 
of fluconazole and itraconazole in prophylactic measures and to treat oropharyngeal and 
vaginal candidiasis (Mulu et al., 2013), making it a less effective drug to combat Candida 
infections. An alternative drug class is the polyenes, such as amphotericin B and nystatin, 
which bind to ergosterol within the cell membrane and create transmembrane channels, 
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leading to membrane instability and cell lysis (Laniado-Laborin, Cabrales-Vargas, 2009). 
Unfortunately, polyenes, especially amphotericin B, have a high affinity for cholesterol 
as well as ergosterol. For this reason, they are associated with numerous negative side 
effects, including renal failure after long-term use (Bondaryk, Kurzatkowski, & 
Staniszewska, 2013). The third class of antifungal drugs, pyrimidine analogs, like 
flucytosine, act like pyrimidine bases, affecting protein synthesis by incorporating into 
RNA and disturbing the normal coding regions (Bondaryk et al., 2013). The main 
enzyme that allows this drug to act, cytosine deaminase, is not present in mammalian 
cells, buffering them from the effects of this drug while acting on the fungal agent.  
However, this class of drugs is usually restricted to use in a multi-drug therapy regimen, 
due to its high incidence of resistance and possible negative side effects, including bone 
marrow suppression and liver dysfunction. The final class of major antifungal drugs is 
echinocandins. This class of drugs acts on the cell membrane of fungi by inhibiting the 
synthesis of 1,3-β-glucan synthase, eventually leading to cell wall instability and cell 
lysis. This drug is effective against azole-resistant Candida yeasts, but has many negative 
side effects including liver toxicity and hemolysis (Bondaryk et al., 2013).  In addition, 
many of the drug interactions between antifungal drugs and other medications are 
negative or can be synergistic, leading to various complications in treatment, especially in 
those which candidiasis as a secondary infection. 
  
The current methods of treatment for candidiasis are neither sufficient nor ideal due to 
their overall high incidence of Candida species resistance and adverse side effects on the 
patient. In addition, the increased occurrence of infection by non-albicans Candida 
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species, which can be resistant to current drug therapies, creates a need for the 
development and investigations of new treatment routes. Histatin 5 
(DSHAKRHHGYKRKFHEKHHSHRGY) is a naturally occurring peptide that resides in 
the saliva of humans and displays strong fungicidal properties, making it a prime model 
for new antifungal drugs (Helmerhorst EJ, 1999). Histatin 5 contains 24 amino acid 
residues and is histidine-rich, making it highly cationic (Oppenheirn et al., 1988). It binds 
to cell wall proteins and glycans upon initial cell interactions. Histatin 5 is then taken up 
by yeast cells through fungal polyamine transporters in an energy dependent manner 
(Puri S & Edgerton M, 2014). Although histatins have been widely studied, their 
mechanism of killing action is not fully mapped out.  
 
There are two current models describing the mechanism of this peptide. One proposal is 
that the entry of histatin 5 ultimately leads to ion imbalance in the fungal cell due to 
increased cell membrane permeability (Wang G, 2014). The second proposal is that the 
target of this peptide is mitochondrial, and that it acts to inhibit the normal respiratory 
pathway of the fungus, causing oxidative stress (Mochon AB and Lui H, 2008). In other 
studies, it has been shown that sodium azide and other respiration inhibitors protect yeast 
cells against the lethal activity of histatin 5 (Helmerhorst EJ, 1999). While this 
observation is useful, chemical manipulation of the cells could affect more than just the 
yeast’s respiratory function. The hope is that by further elucidating the mechanism of 
action for histatin 5 and its derivatives, these peptides can be promoted and explored as 
possible novel antifungal drugs.  
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 KM23, an inverted dimer, is the principal derivative of histatin 5 focused on in this 
study. In Dr. McNabb’s lab, previous work has thoroughly characterized KM12 
(YKRKFC-CFKRKY). This peptide is very similar to KM23 in killing activity, with 
slight structural differences. The LD50 for KM12 on C. albicans was determined to be 
0.308±0.035 µM (Akkam Y, 2013). KM12 had similar ability to kill S. cerevisiae and C. 
albicans. The activity of this derivative, KM12, is ten times more active than histatin 5 
alone (Akkam Y, 2013). KM23 and KM12 are inhibited in the presence of histatin 5 
inhibitors, such as low temperature and sodium azide, and are therefore suggested to have 
a similar mode of action to histatin 5 (Akkam Y, 2013). In order to further map the 
mechanism of action of histatin 5 and its derivatives, the effects of KM23 on the 
genetically tractable model yeast, Saccharomyces cerevisiae, has been tested. 
 
Saccharomyces cerevisiae serves as a good model organism for Candida albicans 
because these organisms are closely related to each other, (Li, Palecek, 2005) and they 
are both susceptible to the killing action of histatin 5 and our derivative peptides. 
Saccharomyces cerevisiae grows rapidly, in small, smooth, cream to tan colored colonies. 
This species of yeast replicates by budding like Candida albicans, but has a haploid 
instead of a diploid genome. S. cerevisiae serves as a prevalent model organism because 
it has well characterized genes and is easily manipulated due to its haploid genome. The 
logic of this study is to identify mutations in the electron transport chain, more 
specifically the ATP synthase of S. cerevisiae, that confer resistance to KM23. Any 
mutant that causes resistance to killing by KM23 is likely involved in the peptide’s 
mechanism of killing action, which we hypothesize is localized in the mitochondria. 
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Unlike, chemical means of testing for killing inhibition, testing genetic knockouts focuses 
on a single trackable protein subunit. In other studies, it has been shown that respiratory 
enzyme complexes, including proteins involved in the ATP synthase gamma chain and 
malate dehydrogenase, were mostly down-regulated when Candida albicans was treated 
with histatin 5 (Komatsu T, 2011). S. cerevisiae mutants located in the ATP synthase of 
the electron transport chain, including atp1∆, atp2∆, atp5∆ and atp7∆, were tested to 
examine KM23’s mechanism of action.  
 
Figure 1. ATP synthase and S. cerevisiae respiratory mutants. Figure adapted from 
Rak M, 2011. Yeast mitochondrial ATP synthase protein subunits and corresponding 
knockout mutants.  
 
 
The F1F0-ATP synthase of S. cerevisiae consists of two functional domains, the globular 
F1 protein and the membrane-bound F0 protein. These two domains couple to catalyze 
ATP synthesis and proton translocation across the inner mitochondrial membrane (Rak 
2011). The electroosmotic potential created by the transport of protons across the 
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membrane is used to synthesize ATP from ADP and Pi. These two functional domains are 
connected by both a central and a stator stalk (Devenish 2000). This connection aids in 
the rotation of subunits within the enzyme that catalyzes the movement of protons across 
the inner membrane. The various protein subunits of the F1F0-ATP synthase of S. 
cerevisiae were knocked out and purchased as a library. atp1Δ, atp2Δ, atp5Δ, and atp7Δ 
were tested (Figure 1). While these mutants are essential to ATP synthase functioning, 
their deletion is not lethal to the yeast cells.  These mutants are still able to undergo 
fermentation to produce ATP on YPD medium (Norais 1991). However, any substrate 
that cannot be utilized through glycolysis and alcoholic fermentation, glycerol for 
example, will inhibit the growth of the mutant yeast strains. 
 
The atp1Δ and atp2Δ are subunits of the F1 functional domain of the mitochondrial ATP 
synthase (Takeda 1986). They comprise an alternating hexamer of catalytic subunits that 
are involved in ATPase activity. atp1Δ is a knockout mutation of the α-subunit and atp2Δ 
is a knockout mutation of the β-subunit of the F1 functional domain (Takeda 1986, 1985). 
atp5Δ and atp7Δ are mutations of subunits within the stator stalk of ATP synthase 
(Devenish 2000). atp5Δ is the OSCP or oligomycin sensitivity-conferring protein (Boyer 
1997) and atp7Δ is a knockout mutation of the d-subunit of the stator stalk (Norais 1991). 
Both of these subunits are normally involved in proton translocation and rotation of the 
F1 and F0 functional domains.  
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Methods and Materials 
Saccharomyces cerevisiae strains and growth media. The wild-type Saccharomyces 
strain was BY4741 (MATa, his3Δ1, leu2Δ0, met15Δ0, ura3Δ0). In addition, four 
mitochondrial ATP synthase mutants, atp1Δ, atp2Δ, atp5Δ, and atp7Δ were used in this 
study.  The mutants were isogenic derivatives of BY4741 and they were purchased from 
Dharmacon as part of a genome-wide S. cerevisiae knockout collection.   All strains were 
grown in Yeast extract-peptone-dextrose (YPD) liquid culture 24 hours prior to the 
beginning of each assay (Guthrie and Fink, 1991). Strains were grown on YPD agar 
plates during each assay.  Yeast extract-peptone-glycerol (YPG) was prepared as 
described (Guthrie and Fink, 1991). 
 
KM23 peptide. The stock KM23 peptide was purchased from Gene Script, where it was 
synthesized and purified. The 50 µM stock peptide (YKRKFFKRKY) was diluted to 2 
µM with 10 mM phosphate-buffered saline (PBS) for each microdilution assay.  
 
Microdilution Assay. Prior to each independent assay, 5 mL YPD liquid medium was 
inoculated for each S. cerevisiae strain to be tested. These strains were grown at 30°C 
overnight. On the day of the assay, 1 mL of each strain was transferred to a 1.5 mL 
eppendorf tube. The tubes were centrifuged for 10 min at 14,000 rpm. The supernatant 
was discarded, and 1 mL of 10 mM sodium phosphate buffer (PB) was added to each 
tube. The pellet was resuspended, and the tubes were centrifuged for another 10 min at 
14,000 rpm. The supernatant was again discarded. The pellet of each tube was 
resuspended a second time with 1 mL PB and vortexed. The cells were quantified on a 
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hemocytometer. The cell count was input into an Excel counting sheet, which computed 
the amount needed to have 3.6 × 106 cells in 1 mL of PB (10X stock solution of cells). 
This amount of cells, for each respective strain, was inoculated in 1 mL PB. Then in a 
second set of tubes, 900 µL of PB was inoculated with 100 µL of the prepared 10X stock 
of cells to bring the final concentration to 3.6 × 105 cells in 1 mL of PB. Next, 20 µL of 
the diluted cells were placed into two eppendorf tubes: one with 20 µL PB, the other with 
20 µL 2 µM KM23. These eppendorf tubes, two for each strain, were placed in the 
incubator at 30°C and shaken at 320 rpm for 2 hours. After incubation, the tubes were 
removed, and 360 µL of yeast nitrogen base was added to each tube. The tubes were then 
vortexed before being plated. Two replicates of each tube were made on YPD agar plates. 
All of the plates were incubated at 30°C for 48 hours. After this incubation period, the 
colony forming units were counted on each plate. The average of the two replicates was 
taken and the cell viability was calculated.  
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Results 
For evaluating the killing activity of KM23 in each of the strains, a concentration of 
KM23 was chosen that yielded approximately 50% cell viability when used with the 
wild-type strain, BY4741.  Thus, 1 µM final concentration of the KM23 peptide was used 
in these studies.  The logic for this choice was to provide for the ability to observe either 
increased resistance or increased sensitivity to the peptide for the various mutants 
evaluated. 
 
Microdilution assays were performed for the wild-type and the atp1∆, atp2∆, atp5∆ and 
atp7∆ mutants.  It should be noted that the assays were performed in duplicates for each 
trial and a minimum of three independent trials were performed with each mutant.  For 
the wild-type there were thirteen independent experiments, the atp1∆ and atp2∆ mutants 
were tested in five independent trials, and the atp5∆ and atp7∆ mutants were evaluated in 
three independent trials.  After conducting the microdilution assays, the data for all the 
mutants was compiled and statistically analyzed using an unpaired student T-test.  The 
atp1Δ, atp5Δ, and atp7Δ showed significant resistance to KM23, with virtually 100% 
viability after exposure to 1µM KM23 as compared to the wild-type strain, which 
exhibited less than 50% cell viability (Figure 2).  The atp2Δ demonstrated variable results 
and did not show any significant resistance to KM23 (Figure 2). This was a particularly 
surprising and unexpected observation.   Since the atp2Δ mutant was one knockout strain 
from a large collection of over 4,900 individual S. cerevisiae strains, it was plausible that 
the knockout mutation was not correct and that the putative atp2Δ mutant was not as 
advertised by the company from where it was purchased.  
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Figure 2. Mutation in the ATP Synthase confers resistance to KM23.  Microdilution 
assays were performed as described in the Materials and Methods.  Each of the strains 
were evaluated in duplicate with a minimum of three independent trials.  The average 
percent cell viability is shown with the bars indicating the standard error.  The data was 
evaluated using an unpaired student T- test and the statistical significance is indicated.  
NS denotes no statistical difference from the wild-type strain.   
 
In order to address this concern, the wild-type strain and the atp1∆, atp2∆, atp5∆ and 
atp7∆ mutants were streaked on YPD medium, containing glucose as the carbon source, 
and YPG medium, containing glycerol as the carbon source.  Strains that could grow on 
YPG are not respiratory deficient because they are able to generate ATP through 
respiration by the oxidation of glycerol, a three-carbon substrate. Strains that could only 
grow on YPD were able to generate ATP via fermentation of the glucose present in the 
YPD medium, but could not utilize non-fermentable carbon sources.  It was found that 
the wild-type strain grew on YPG as expected. More importantly, it was observed that the 
atp2Δ mutant grew well on YPG medium confirming that it is not respiratory deficient.  
This data suggests that the atp2Δ mutant may not be truly deficient in its abilities to 
respire; hence, our observation that it was not resistant to the KM23 peptide. One can 
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also note that even on YPD, the respiration defective strains are clearly distinguishable by 
the difference in the growth phenotype.  The respiratory mutants (atp1Δ, atp5Δ, atp7Δ) 
failed to grow as robustly as the wild-type or the atp2Δ mutant due to the depletion of 
glucose from the medium. 
 
 
 
Figure 3. The respiratory phenotype of the putative ATP Synthase mutants. The 
wild type, atp1∆, atp2∆, atp5∆ and atp7∆ mutants as indicated were streaked on either 
YPD medium or YPG medium and grown at 30oC for 3 days.    
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Discussion 
Multiple other studies have referenced the possible importance of the mitochondrion in 
the killing mechanism of histatin 5 and its derivatives (Mochon AB and Lui H, 2008) 
(Helmerhorst EJ, 1999). Previous studies used chemical methods, which have led to 
uncertain conclusions and the need for a more targeted approach. Through testing 
respiratory mutants of several subunits within the ATP synthase in S. cerevisiae, we were 
able to specifically target the electron transport chain within the mitochondria. The 
mutants we used were gene knockouts for each subunit within the F1F0-ATP synthase of 
S. cerevisiae. KM23 cannot act without this molecular target within the yeast cell. 
Mutants that conferred resistance to KM23, the histatin 5 derivative peptide, are involved 
in the killing mechanism of the peptide. atp1Δ, atp5Δ, and atp7Δ show this trend, having 
significant resistance to KM23 in comparison to the cell viability of the mutants in the 
presence of the buffer. atp2Δ was not significantly resistant to the lethal effects of KM23; 
however, it was also shown to not be respiratory deficient.  Interestingly though, this 
mutant still provided an unknown internal control for our studies and further emphasized 
the importance of respiration in the killing action of our peptide.  
 
The inability of the atp2Δ mutant to protect itself against KM23 acts as unintentional 
support for our hypothesis. After testing the respiratory abilities of atp2Δ by growing the 
mutants on fermentable and non-fermentable carbon sources, we found that the atp2Δ 
strain was not in fact a full gene knockout. It was able to grow on YPG, forcing the cells 
to respire using glycerol as the primary carbon source and thereby, the electron transport 
chain to produce energy (Figure 3). Therefore, the atp2Δ strain that we assumed did not 
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have a functional ATP synthase, did in fact have the enzyme. KM23 was able to bind to 
and act on this strain, just as it could in the wild-type yeast, because the intracellular 
target was present. This study shows that ATP synthase activity in S. cerevisiae is crucial 
to the killing activity of KM23. 
 
Further support for the role of the mitochondria in the mechanism of KM23 activity 
comes from the recent Honors thesis of Gabriela Morris, another student in the McNabb 
laboratory.  In those studies, the KM23 peptide was fluorescently labeled and fluorescent 
microscopy was used to determine the intracellular localization of the peptide.  It was 
found that KM23 localizes exclusively to the mitochondria, lending further support to the 
model that respiratory metabolism is important for the killing mechanism of KM23.   
 
The question arises as to whether other mutations in the electron transport chain would 
yield similar KM23-resistant phenotypes or whether this is exclusively associated with 
the ATP synthase.  Future studies should be directed toward examining mutants in 
subunits of Complex I, Complex II, Complex III and Complex IV of the electron 
transport chain to determine whether those mutations confer resistance to KM23.  
Nevertheless, identifying the target pathways involved in peptide resistance does not 
provide details on the mechanism by which the KM23 peptide is fungicidal. Since S. 
cerevisiae does not require functional respiration for survival, it poses the question as to 
why mutations that abolish respiration result in resistance to the peptide.  Is abundant 
ATP production essential?  Does reduced ATP synthesis influence other pathways, such 
as energy-dependent transporters, that may be the actual target of KM23 killing?  
18 
 
In order to further study the mechanism of KM23 it must be determined whether 
respiration in general is required for the lethal activity of KM23, or whether the 
intracellular target is more specific. In the McNabb lab, students are currently screening a 
library of approximately 5000 S. cerevisiae mutants to determine all possible genetic 
pathways involved in the fungicidal activity of KM23. This includes mutations within the 
other complexes of the electron transport chain.  In addition, it will be important in future 
studies to test respiratory mutants in C. albicans and other Candida species to compare 
the pathways affected by KM23.  
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